GPT and metabolic dysfunction-associated steatotic liver disease: Studies in pediatric patients with NAFLD have also been developed, the most prominent being the RCT of Nobili et al. [64] using docosahexaenoic acid (DHA) treatment (250 and 500 mg/day) versus placebo in 60 pediatric patients with NAFLD, with evaluation of the changes in the fat liver content by ultrasonography after 6, 12, 18 and 24 months of intervention, and changes in TGs, ALT, BMI, and the homeostatic model assessment (HOMA) index of insulin resistance.